A Case of Abiraterone-Related Hypokalemia Leading to Torsades de Pointes and Cardiac Arrest

Abiraterone acetate is an androgen-depriving therapy (ADT) that is highly effective for treating castration-resistant prostate cancer (CRPC). By inhibiting CYP17, abiraterone can induce a state of mineralocorticoid excess, which is associated with profound hypokalemia. We present a case of abiraterone-related hypokalemia which led to torsades de pointes (TdP) and ventricular fibrillation (VF). We reviewed the literature and showed the need for close monitoring of the potassium level and electrocardiogram (ECG) to prevent fatal arrhythmias.

Automated summary

Abiraterone acetate is an effective therapy for castration-resistant prostate cancer, but it can lead to severe hypokalemia. This article presents a case report and literature review emphasizing the importance of monitoring potassium levels and electrocardiogram to prevent fatal arrhythmias.